Log In
Print
BCIQ
Print
Print this Print this
 

Patrome (Rytary) (GSK587124, IPX066)

Also known as: second generation carbidopa/levodopa

  Manage Alerts
Collapse Summary General Information
Company Impax Laboratories Inc.
DescriptionExtended-release combination of carbidopa and levodopa
Molecular Target Not available
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentApproved
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat advanced Parkinson's disease (PD); Treat idiopathic Parkinson's disease (PD); Treat Parkinson's disease (PD)
Regulatory Designation

U.S. - Special Protocol Assessment (Treat Parkinson's disease (PD));
U.S. - Undisclosed Review (Treat idiopathic Parkinson's disease (PD));
EU - Standard Review (Treat idiopathic Parkinson's disease (PD))

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$186.5M

$11.5M

$175.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today